Financing – September 30, 2026
Danish biotech Breye Therapeutics has closed an oversubscribed EUR 67.5 million Series A financing to advance danegaptide, its first-in-class oral treatment for non-proliferative diabetic retinopathy (NPDR), into a Phase II clinical trial.
MedTech Business – September 30, 2026
The company has signed a new contract with a leading US hospital network that operates multiple hospitals in the eastern United States. The contract covers an initial installation of 60 next-generation TetraGraph systems for monitoring patients under anaesthesia.
New Market – September 29, 2026
Egetis Therapeutics has received FDA approval for Emcitate (tiratricol), making it the first approved treatment in the US for patients with the rare genetic disease MCT8 deficiency. With the approval, the company also received a Rare Pediatric Disease Priority Review Voucher.
Collaboration – September 29, 2026
The company is investing USD 2 billion in Summit Therapeutics and launching a clinical collaboration that will combine Summit’s PD-1/VEGF bispecific antibody ivonescimab with AstraZeneca’s antibody drug conjugates (ADCs), starting in gastrointestinal cancers.
Agreement – September 29, 2026
The company has signed an exclusive license agreement with China’s Hengrui Pharma for HRS-1596, a once-weekly oral GLP-1/GIP dual receptor agonist, in a deal worth up to USD 2.6 billion.
Clinical Trials – September 29, 2026
All planned patient visits have now been completed in the company’s Phase III HEEALING1 study of linaprazan glurate in erosive GERD. Topline results are still expected in Q4 2026.
Clinical Trials – September 29, 2026
All planned patient visits have now been completed in the company’s Phase III HEEALING1 study of linaprazan glurate in erosive GERD. Topline results are still expected in Q4 2026.
Clinical Trials – September 29, 2026
Long-term follow-up of the DiAPREV-IT trial shows that two subcutaneous injections of retogatein (GAD-alum) delayed progression to insulin-dependent, stage 3 type 1 diabetes by more than five years in a genetically defined subgroup of children.
Clinical Trials – September 28, 2026
Cereno Scientific has reported positive topline results from a Phase I pharmacokinetic (PK) bridging study of its HDAC inhibitor CS014. The results strengthen the company’s plan to take the drug candidate directly into a Phase IIb trial in pulmonary hypertension associated with interstitial lung disease (PH-ILD), without a Phase IIa trial or further non-clinical safety studies.
Clinical Trials – September 14, 2026
ResoTher Pharma has reported promising Phase 2a results for its cardioprotective drug candidate RTP-026, moving the company a step closer to a key efficacy trial and a potential pharma partnership or sale.
Clinical Trials – September 9, 2026
In the phase 3 STEP Young trial, 40.4% of children aged 6 to under 12 treated with once-weekly semaglutide were no longer classified as having obesity after 68 weeks, compared with none of those on placebo.
Clinical Trials – September 8, 2026
A post-hoc analysis of SynAct Pharma’s Phase 2b ADVANCE study confirms earlier positive results for resomelagon in rheumatoid arthritis (RA), and the company now plans to discuss Phase 3 trial design with the FDA in Q4 2026.
Confidential
PharmaRelations is recruiting a Medical Device Auditor, on behalf of an innovative and fast-growing organization operating at the intersection of medical technology, regulatory compliance, and advanced digital solutions.
PharmaRelations
PharmaRelations is the Nordic market leader within talent services for the life science industry. We specialize in partnering with some of the top and most innovative organizations exclusively in the Life Science sector across our region. We add value to our clients and candidates with our consultancy services, outsourcing solutions and recruitment of specialists and leaders.
Karl Storz Endoskop Sverige AB
KARL STORZ är ett tyskt medicintekniskt företag som specialiserar sig på tillverkning och försäljning av endoskopisk utrustning och kirurgiska instrument. Företaget grundades 1945 i Tuttlingen av Dr. Karl Storz och har en lång historia av innovation inom medicinsk teknik.
PharmaRelations
Stillingen er 100 % remote med en forventet arbejdsbelastning på ca. 0-20 timer pr. måned, afhængigt af projektbehov.
PharmaRelations
You will have the opportunity to work in a team of PV specialists, helping our clients with the best solutions depending on their needs.
Micrel Medical Device
On behalf of Micrel Medical Devices, we are looking for an ambitious and commercially driven Area Sales Manager to develop and grow the Danish market in a newly established position.
In a new job – September 21, 2026
Bavarian Nordic has appointed Tarja Stenvall as President and Chief Executive Officer, effective 15 October. She succeeds Paul Chaplin, whose departure was announced earlier this year.
In a new job – September 17, 2026
Over the course of her career, Anna Sundin has worked on numerous transactions spanning capital raises, IPOs, M&A, and debt financing, as well as providing strategic advice to companies in a growth phase.
In a new job – September 14, 2026
Danish biotech Initiator Pharma has appointed Annette Säfholm, PhD, as Chief Operating Officer (COO) and a member of the company’s management team, strengthening its business development and operational capacity as it approaches topline data from its Phase IIa study of pudafensine in vulvodynia.
Career choice – September 14, 2026
From Stanford’s sunlit engineering quad to SciLifeLab’s brisk knowledge hub in Stockholm, Emma Lundberg works across two distinct innovation cultures. She sees lessons for Sweden in Silicon Valley’s close links between academia, investors, and industry, but also strengths at home that should not be lost.
Careers article – August 14, 2026
Returning to work after a long, relaxing vacation can be challenging. Here are some tips to make the transition easier and less stressful.
Careers article – July 19, 2026
Thomas Karikari’s career has taken him across three continents: from Ghana to the UK and Sweden, and then to the US. Now an Associate Professor at the University of Pittsburgh and one of Nature Index’s “rising stars in ageing research”, he is helping move Alzheimer’s blood biomarkers beyond individual markers and towards a more complete picture of disease biology.
Profiles in Business – September 24, 2026
As HealthCap marks 30 years of life science investing, co-founder Björn Odlander reflects on the firm’s long-term approach, the journey from lab to patient, and Europe’s widening capital gap.
Profiles in Business – September 22, 2026
Throughout her career, customer centricity and a passion for addressing unmet medical needs have driven Norwegian Lena Nymo Helli. This year, she joined the Danish company Coloplast as Country Manager for Norway.
Business Award – September 18, 2026
Teitur Trophics’ co-founder and CEO Simon Mølgaard was named Rising Star in Danish Biotech at the DANISH BIO – Dansk Biotek Spring Gala in April 2026. Nordic Life Science asked him about the transition from science to business, building a company from Aarhus, and the opportunities ahead in treating neurodegenerative disease.
Pharma Business – September 25, 2026
The company will relocate its US headquarters from Deerfield, Illinois, to Greater Boston, Massachusetts, where it will also establish a global innovation hub. The move is part of the next phase of the company’s Focused Innovator strategy.
Agreement – September 25, 2026
Nanexa has entered into a global exclusive license and collaboration agreement with Novo for the use of the PharmaShell technology platform for certain peptide-based drugs targeting obesity, type 2 diabetes and other cardiometabolic indications.
Financing – September 24, 2026
The Helsinki-based company has closed a EUR 30 million Series A round led by Hadean Ventures to take its lead candidate, a TrkB potentiator designed to deliver the benefits of psychedelics without the hallucinations, into clinical trials for major depressive disorder.
MedTech Business – September 28, 2026
Arjo has presented a new strategy at its Capital Markets Day, committing to improve EBIT by approximately SEK 350 million (±25 million) compared with 2025, by mid-2029.
MedTech Business – September 16, 2026
The company is to separate its Operating Room Solutions (ORS) and Gloves businesses into a new standalone company, provisionally named ‘Mölnlycke Surgical’, while Wound Care and Antiseptics continue as Mölnlycke.
Collaboration – September 14, 2026
RaySearch Laboratories and US-based Accuray have entered a definitive agreement to expand their collaboration on online adaptive radiation therapy, with Accuray committing to purchase RayStation software licences worth USD 8 million.
Biotech Business – September 24, 2026
Swedish biotech company MucoShield is developing a locally administered, fast-acting treatment to protect the oral mucosa during chemotherapy and prevent severe chemotherapy-induced oral mucositis, one of the most painful and debilitating side effects of cancer treatment.
Biotech Business – September 23, 2026
BioArctic’s Alzheimer’s drug Leqembi is now available at a private clinic in Stockholm, where the first patient in Sweden to receive the drug outside a clinical trial started treatment on September 22. This comes five months after the NT Council advised Sweden’s regions against using it.
Biotech Business – September 22, 2026
Elicera Therapeutics has received approval from the Swedish Medical Products Agency (Läkemedelsverket) to move its CARMA study of the CAR T-cell therapy ELC-301 in B-cell lymphoma into Phase IIa.
Science News – September 28, 2026
SciLifeLab is increasing its space on Campus Solna by more than 9,000m². Property owner Akademiska Hus is investing approximately SEK 230 million in an extensive renovation that will give the research center more modern laboratories, flexible workspaces, and new facilities for meetings and training.
Science News – September 25, 2026
Cancer rates among adults under 50 rose for 12 of 18 cancer types in the Nordic countries between 2003 and 2022, according to a registry study published in The Lancet Regional Health – Europe. The study analyzed more than 2.2 million cancer cases from Sweden, Denmark, Finland, Iceland, Norway, the Faroe Islands and Greenland, covering nearly 28 million people.
Science News – September 24, 2026
Patients who have had high-risk polyps removed can probably wait five years rather than three for their first follow-up colonoscopy without raising their risk of colorectal cancer. That is the finding from the European Polyp Surveillance (EPoS) trial, the world’s largest randomized study of follow-up after polyp removal, led from Oslo University Hospital and the University of Oslo. The first results were published in the New England Journal of Medicine.
This site uses cookies
